Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Working Capital Changes (2018 - 2025)

BioNexus Gene Lab's Other Working Capital Changes history spans 8 years, with the latest figure at $57720.0 for Q3 2025.

  • For Q3 2025, Other Working Capital Changes rose 2880.35% year-over-year to $57720.0; the TTM value through Sep 2025 reached $93410.0, up 386.89%, while the annual FY2024 figure was $95879.0, 514.65% up from the prior year.
  • Other Working Capital Changes for Q3 2025 was $57720.0 at BioNexus Gene Lab, up from -$74087.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $120221.0 in Q4 2024 and bottomed at -$104876.0 in Q4 2022.
  • The 5-year median for Other Working Capital Changes is -$6275.0 (2021), against an average of -$5606.1.
  • The largest annual shift saw Other Working Capital Changes crashed 419.99% in 2022 before it soared 2880.35% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$20169.0 in 2021, then plummeted by 419.99% to -$104876.0 in 2022, then surged by 92.16% to -$8218.0 in 2023, then skyrocketed by 1562.9% to $120221.0 in 2024, then plummeted by 51.99% to $57720.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Other Working Capital Changes are $57720.0 (Q3 2025), -$74087.0 (Q2 2025), and -$10444.0 (Q1 2025).